CIAMBRA Powder for concentrate for solution for infusion Ref.[49900] Active ingredients: Pemetrexed

Source: European Medicines Agency (EU)  Revision Year: 2022  Publisher: Menarini International Operations Luxembourg S.A., 1, Avenue de la Gare, L-1611, Luxembourg, Luxembourg

Product name and form

CIAMBRA 100 mg powder for concentrate for solution for infusion.

Pharmaceutical Form

Powder for concentrate for solution for infusion.

White to almost white lyophilised powder.

The pH of the reconstituted solution is between 6.6 and 7.8.

The Osmolality of the reconstituted solution is 230-270 mOsmol/kg.

Qualitative and quantitative composition

One vial of powder contains 100 mg of pemetrexed (as pemetrexed disodium hemipentahydrate).

After reconstitution (see section 6.6), each vial contains 25 mg/ml of pemetrexed.

Excipient with known effect: Each vial contains approximately 11 mg sodium.

For the full list of excipients, see section 6.1.

Active Ingredient Description
Pemetrexed

Pemetrexed is a folate analog metabolic inhibitor that exerts its action by disrupting folate-dependent metabolic processes essential for cell replication. In vitro studies have shown that pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), glycinamide ribonucleotide formyltransferase (GARFT) and and to a lesser extent aminoimidazole carboxamide ribonucleotide formyltransferase (AICARFT), which are folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides. Pemetrexed is taken into cells by membrane carriers such as the reduced folate carrier and membrane folate binding protein transport systems. Once in the cell, pemetrexed is converted to polyglutamate forms by the enzyme folylpolyglutamate synthetase. The polyglutamate forms are retained in cells and are inhibitors of TS and GARFT. Polyglutamation is a time- and concentration-dependent process that occurs in tumor cells and, is thought to occur to a lesser extent, in normal tissues. Polyglutamated metabolites are thought to have an increased intracellular half-life resulting in prolonged drug action in malignant cells.

List of Excipients

Mannitol (E421)
Hydrochloric acid (for pH adjustment)
Sodium hydroxide (for pH adjustment)

Pack sizes and marketing

Type I glass vial with chlorobutyl rubber stopper and an aluminium seal with flip off cap. The vial is covered with a shrink-wrapped plastic sleeve. Each 10 ml vial contains 100 mg of pemetrexed (as pemetrexed disodium hemipentahydrate).

Pack of 1 vial.

Marketing authorization holder

Menarini International Operations Luxembourg S.A., 1, Avenue de la Gare, L-1611, Luxembourg, Luxembourg

Marketing authorization dates and numbers

EU/1/15/1055/001

Date of first authorisation: 2 December 2015
Date of latest renewal: 23 July 2020

Drugs

Drug Countries
CIAMBRA Austria, Estonia, Croatia, Ireland, Lithuania, Poland, Romania

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.